Therapeutic | Ublituximab |
Target | MS4A1 |
Heavy Chain | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS |
Light Chain | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | EMABling Platform |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | LFB Biotechnologies%3BrEVO Biologics%3BJohns Hopkins University%3BTG Therapeutics Inc |
Conditions Approved | na |
Conditions Active | Chronic lymphocytic leukaemia%3BMultiple sclerosis%3BDiffuse large B cell lymphoma%3BFollicular lymphoma%3BMantle-cell lymphoma%3BNon-Hodgkin%27s lymphoma%3BNeuromyelitis optica |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]